透過您的圖書館登入
IP:3.17.184.90
  • 期刊

Beneficial Effects of Enalapril on Chlorhexidine Digluconate-Induced Liver Peritoneal Fibrosis in Rats

並列摘要


Peritoneal fibrosis (PF) is a recognized complication of long-term peritoneal dialysis (PD) and can lead to ultrafiltration failure. The present study was designed to investigate the protective effects of enalapril on chlorhexidine digluconate-induced liver PF by decreasing transforming growth factor-β1 (TGF-β1) production in rats. PF was induced in Sprague-Dawley rats by daily administration of 0.5 ml 0.1% chlorhexidine digluconate in normal saline via PD tube for one week. Rats received daily intravenous injections of low dose enalapril (1 mg/kg), or high dose enalapril (2.5 mg/kg), for one week. After 7 days, conventional 4.25% Dianeal (30 ml) was administered via a PD catheter with a dwell time of 4 h and assessment of peritoneal function. At the end of dialysis, the rats were sacrificed and liver peritoneum was harvested for microscopic examination and immunohistochemistry. There was no significant difference in mean arterial pressure and heart rate between groups. After 4 h of PD, the D4/P4(subscript urea) level was reduced, the D4/D0 glucose level, serum and the dialysate TGF-β1 level was increased, the liver peritoneum was markedly thicker, and the expression of TGF-β1, alpha-smooth muscle actin (α-SMA), fibronectin, collagen and vascular endothelial growth factor (VEGF) were elevated in the PF group compared with the vehicle group. High dose of enalapril decreased the serum and dialysate TGF-β1 levels, decreased the thickness of the liver peritoneum, and decreased the expression of TGF-β1, α-SMA, fibronectin, collagen and VEGF-positive cells in the liver peritoneum. Low dose of enalapril did not protect against chlorhexidine digluconate-induced PF in the rat. Enalapril protected against chlorhexidine digluconate-induced PF in rats by decreasing TGF-β1 production.

參考文獻


Aroeira, L. S.,Aguilera, A.,Sánchez-Tomero, J. A.,Bajo, M. A.,del Peso, G.,Jiménez-Heffernan, J. A.,Selgas, R.,López-Cabrera, M.(2007).Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions.J. Am. Soc. Nephrol..18,2004- 2013.
Atlas, S. A.(2007).The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.J. Manag. Care Pharm..13(8 Suppl B),9-20.
Augustine, T.,Brown, P. W.,Davies, S. D.,Summers, A. M.,Wilkie, M. E.(2009).Encapsulating peritoneal sclerosis: clinical significance and implications.Nephron Clin. Pract..111,c149-c154.
Augustyniak, R. A.,Maliszewska-Scislo, M.,Chen, H.,Fallucca, J.,Rossi, N. F.(2007).Acute angiotensin-converting enzyme inhibition evokes bradykinin-induced sympathetic activation in diabetic rats.Am. J. Physiol. Regul. Integr. Comp. Physiol..293,R2260-R2266.
Carvajal, G.,Rodríguez-Vita, J.,Rodrigues-Díez, R.,Sánchez- López, E.,Rupérez, M.,Cartier, C.,Esteban, V.,Ortiz, A.,Egido, J.,Mezzano, S. A.,Ruiz-Ortega, M.(2008).Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation.Kidney Int..74,585-595.

被引用紀錄


吳欣宜(2015)。使用隱形偏光標記及可見光通訊之室內擴增實境導航系統〔碩士論文,國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2015.00703

延伸閱讀